Note: Descriptions are shown in the official language in which they were submitted.
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW110477P00090PC
METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND
METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
BACKGROUND OF THE INVENTION
[001] Hyperuricemia is defined by values of blood uric acid over 6.8 to
7.0 mg/dL in men or over 6 mg/dL in women. Hyperuricemia and metabolic
disorders associated with hyperuricemia, such as gout, affect 3 to 5 million
individuals in the United States. In the United States, African Americans are
twice as likely as Caucasian Americans to have gout. Further, gout and
hyperuricemia have become common in China, Japan, Polynesia and urban
sub-Saharan Africa, with rates of gout approximately doubling between 1990
and 2010. This rise in the incidence of the disease is believed to be due to a
longer life expectancy, changes in diet, alcohol consumption and an increase
in
diseases associated with gout, such as metabolic syndrome, renal insufficiency
and hypertension. A number of factors have been found to influence rates of
gout, including age, race, and the season of the year. In men over the age of
30
and women over the age of 50, prevalence of gout is approximately two
percent.
[002] The metabolic disorders associated with hyperuricemia include
not only gout, but also painful attacks of acute, monarticular, inflammatory
arthritis due to uric acid crystals, deposition of urate crystals in joints,
deposition
of urate crystals in renal parenchyma, urolithiasis, nephrolithiasis and gouty
nephropathy. Long term nephrolithiasis and gouty nephropathy are known to
increase the risk of kidney damage and kidney failure.
[003] Gout is a medical condition usually characterized by recurrent
- 1 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW110477P00090PC
attacks of acute inflammatory arthritis. The metatarsal-phalangeal joint at
the
haca of the big tnca is the riloqt Commonly pf-fprtpri (in about of rasps).
However, gout may also present as tophi, kidney stones or urate nephropathy.
Gout is believed to be caused by elevated levels of uric acid in the blood
which
crystallize and are deposited in joints, tendons, and surrounding tissues.
[004] Current treatments for hyperuricemia and gout include lowering
the blood concentration of uric acid by urate-lowering agents, such as: 1)
xanthine oxidase inhibitors, such as allopurinol and febuxostat; 2) uricosuric
agents, such as sulphinpyrazone, benzbromarone and probenecid; 3) urate
oxidases, such as pegloticase, puricase, rasburicase and pegylated uricase;
and 4) fenofibrate. In addition, the symptoms of acute gout may be controlled
by anti-inflammatory agents, such as: 1) non-steroidal anti-inflammatory drugs
(NSAIDs), such as indomethacin and ibuprofen; 2) corticosteroids; and 3)
colchicine. Bringing the blood uric acid levels back to the normal range may
decrease the incidence of the recurrent acute gout and prevent other metabolic
disorders associated with hyperuricemia.
[005] However, many of the currently available treatments for gout or
hyperuricemia are associated with a variety of adverse side effects. For
example, xanthine oxidase inhibitors, such as allopurinol, are associated with
hypersensitivity angiitis, Stevens-Johnson syndrome, exfoliative dermatitis,
plastic anemia, and hepatic insufficiency. Uricosuric agents, such as
probenecid, bucolome and benzbromarone, have such side effects as
gastrointestinal disorders, urinary lithiasis; and fulminant hepatic failure
in
patients with idiosyncrasies. Further, probenecid may affect the excretion of
such drugs as captopril, indomethacin, ketoprofen, ketorolac, naproxen,
- 2 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
cephalosporins, quinolones, penicillins, methotrexate, zidovudine, gancyclovir
and acyclrwir. Long term use of NsAinq may 1Rari to side effects, including
ulcer perforation and upper gastrointestinal bleeding.
[006] Therefore, there is still a need to develop new agents for the
treatment of gout and hyperuricemia.
SUMMARY OF THE INVENTION
[007] The present invention provides therapeutic methods for the
treatment and/or prevention of hyperuricemia and metabolic disorders
associated with hyperuricemia, such as gout, gout arthritis, gout flares, uric
acid
nephrolithiasis and gouty nephropathy. The methods are especially suitable for
hyperuricemic patients who have inadequate medical control or cannot tolerate
the currently available urate-lowering and anti-inflammatory therapies.
[008] In particular, the methods of using a therapeutically effective
amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog,
a
prodrug, or an active metabolite thereof to treat and/or prevent hyperuricemia
and metabolic disorders associated with hyperuricemia offer unexpected
advantages in decreasing the blood uric acid levels as compared to the use of
the currently available pharmaceutical agents.
[009] Diacerein, [4, 5- bis(acetyloxy)-9, 10- dioxo-2-anthracene
carboxylic acid], is a highly purified anthraquinone derivative. It has been
approved as a SYmptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA) in
several countries. Rhein is the major active metabolite of diacerein.
Diacerein
has been demonstrated to inhibit the synthesis and activity of proinflammatory
- 3 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
Tw110477P00090PC
cytokines such as interleukin-1 (IL-1), TNF-a and interleukin-6 (IL-6).
[010] According to the present invention, diacerein can decrease and
maintain blood uric acid levels within the normal range during the treatment
period of patients with hyperuricemia and metabolic disorders associated with
hyperuricemia. Further, diacerein can also prevent the recurrence of acute
gout
arthritis and gout flares, whether it is used as the sole active drug (i.e.,
diacerein monotherapy) or in a combination with other urate-lowering and/or
anti-inflammatory agents.
[011] Accordingly, in one embodiment, the invention provides a method
of treating and/or preventing hyperuricemia or a metabolic disorder associated
with hyperuricemia comprising administering to a patient in need thereof a
therapeutically effective amount of a compound selected from the group
consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically acceptable
salt,
an analog, a prodrug, or an active metabolite thereof.
[012] In another embodiment, the method of treating and/or preventing
hyperuricemia or a metabolic disorder associated with hyperuricemia may
further comprise administering to said patient at least one additional
therapeutic
agent selected from the group consisting of anti-inflammatory agents and
urate-lowering agents.
[013] In another embodiment, the invention provides a method of
improving blood uric acid level control in a patient with gout, hyperuricemia
or a
metabolic disorder associated with hyperuricemia comprising administering to
said patient a therapeutically effective amount of a compound selected from
the
- 4 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
group consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically
acceptable
salt, an analog, a prodrug, or an active metabolite thereof.
[014] In another embodiment, the invention provides a method of
treating and/or preventing hyperuricemia or a metabolic disorder associated
with hyperuricemia in a patient receiving a urate-lowering agent or an
anti-inflammatory agent, comprising administering to said patient a
therapeutically effective amount of a compound selected from the group
consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically acceptable
salt,
an analog, a prodrug, or an active metabolite thereof.
[015] In yet another embodiment, the invention provides a method of
treatment for hyperuricemia or a metabolic disorder associated with
hyperuricemia in a patient with poor tolerance to therapeutic agents selected
from the group consisting of anti-inflammatory agents and urate-lowering
agents, comprising administering to Said patient a therapeutically effective
amount of a compound selected from the group consisting of: 1) diacerein, 2)
rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an
active metabolite thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[016] Figure 1 is a graph demonstrating blood uric acid levels in male
patients treated with either diacerein or placebo.
[017] Figure 2 is a graph demonstrating blood uric acid levels in female
patients treated with either diacerein or placebo.
- 5 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW110477P00090PC
DETAILED DESCRIPTION OF THE INVENTION
[018] According to the present invention, diacerein, rhein, or a
pharmaceutically acceptable salt, an analog, a prodrug, or an active
metabolite
thereof can be used for the treatment and/or prevention of hyperuricemia and
metabolic disorders associated with hyperuricemia, such as gout, gout
arthritis,
gout flares, uric acid nephrolithiasis and gouty nephropathy.
[019] Treatment of hyperuricemia aims to reduce the blood levels of
uric acid to the normal range. In humans, the upper end of the normal range of
blood uric acid levels is about 6 mg/dL for women and about 7.0 mg/dL for men.
These ranges are subject to change depending on updated clinical guidelines.
Treatment of gout aims to relieve pain and inflammation of the acute attack
and
reduce the incidence of recurrent attacks.
[020] Use of diacerein, rhein and pharmaceutically acceptable salts,
analogs, prodrugs, or active metabolites thereof to treat and/or prevent
hyperuricemia and metabolic disorders associated with hyperuricemia, such as
gout, offers unexpected advantages compared to the use of conventional
treatments. These advantages include the ability to decrease blood uric acid
levels and to prevent the recurrence of gout symptoms. In addition, in some
embodiments of the invention, the methods of the present invention allow for
oral administration of the drug, thus avoiding injection-site adverse
reactions.
[021] As used herein, diacerein (4, 5- bis(acetyloxy)-9,
dioxo-2-anthracene carboxylic acid) refers to a compound having the following
structural formula:
- 6 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
0
Q
Ole*
= H
[022] Diacerein directly inhibits IL-1t3 synthesis and modulates IL-1i3
induced activities. Diacerein has been shown to have disease modifying effect
in experimental models of osteoarthritis and in human subjects with finger
joint
and knee osteoarthritis. IL-16 plays a fundamental role in osteoarthritis
pathophysiology and cartilage destruction. IL-16 also promotes the expression
of inducible nitric oxide synthase, and increases the release of prostaglandin
E2, IL-6, IL-8 and TNF-a in human osteoarthritis chondrocytes.
[023] Pharmaceutically acceptable salts, analogs, prodrugs and active
metabolites of diacerein are also contemplated for use in this invention.
Rhein
(9,10-dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid) and
monoacetylrhein are the known active metabolites of diacerein.
[024] As used herein, the term "pharmaceutically acceptable salts"
includes salts of acidic or basic groups. Examples of pharmaceutically
acceptable salts include those derived from inorganic acids, such as
hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,
monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as
the salts derived from relatively nontoxic organic acids, such as acetic;
propionic; isobutyric; maleic; malonic; benzoic; succinic; suberic; fumaric;
mandelic; phthalic; benzenesulfonic; toluenesulfonic, including
- 7 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
p-toluenesulfonic, m-toluenesulfonic, and o-toluenesulfonic; citric; tartaric;
methanesulfonic; and the like. Also included are salts of amino acids such as
arginate and the like, and salts of organic acids, such as glucuronic or
galacturonic acids and the like.
[025] As used herein, the term "prodrug" refers to a pharmacologically
inactive derivative of an active drug designed to convert into the active drug
through in vivo physiological action, such as hydrolysis, metabolism and the
like.
[026] As used herein, the term "urate-lowering agent" refers to a drug
used to treat gout and hyperuricernia by lowering uric acid levels in the
blood.
Examples of the currently available urate-lowering agents include, but not
limited to, 1) xanthine oxidase inhibitors, such as allopurinol and
febuxostat; 2)
uricosuric agents, such as sulphinpyrazone, benzbromarone and probenecid; 3)
urate oxidase inhibitors, such as pegloticase, puricase, rasburicase and
pegylated uricase; and 4) fenofibrate. Those drugs can be given alone or in a
corn bination.
[027] As used herein, the term "anti-inflammatory agent" refers to a
drug used to treat inflammatory symptoms of gout and hyperuricemia.
Examples of the currently available anti-inflammatory agents include, but not
limited to, 1) non-steroidal anti-inflammatory drugs (NSAIDs), such as
indomethacin and ibuprofen, 2) corticosteroids, and 3) colchicine.
[028] As used herein, the terms "treatment" and "treating" include
inhibiting the disease or condition, causing a reduction in severity and/or
frequency of symptoms, elimination of symptoms and/or underlying cause,
- 8 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TVVI10477P00090PC
prevention of the occurrence of symptoms and/or their underlying cause,
ameliorating and/or improving a patient's condition. Thus, "treating" a
patient
with said compositions of the invention includes prevention of a particular
disorder in a susceptible individual, as well as management of a clinically
symptomatic individual to inhibit or cause regression of a disorder or
disease,
and maintenance of the current state and/or prevention of a progression of a
disorder or disease. Treatment can include prophylaxis, therapy, or cure.
[029] As used herein, the term "therapeutically effective amount" of the
compounds and/or pharmaceutical compositions of the invention refers to a
sufficient amount of the compound and/or composition to treat, inhibit,
ameliorate or prevent hyperuricemia or metabolic disorders associated with
hyperuricemia, at a reasonable benefit/risk ratio applicable to any medical
treatment. It will be understood, however, that the total daily usage of the
compounds and/or compositions of the present invention will be decided by the
attending physician within the scope of sound medical judgment. The specific
effective dose level for any particular patient will depend upon a variety of
factors, including the disorder being treated and the severity of the
disorder;
activity of the specific compound employed; the specific composition employed;
the age, body weight, general health, sex and diet of the patient; the time of
administration, route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed; and like factors well
known in the medical arts. For example, it is well within the skill of the art
to
start doses of the composition at levels lower than required to achieve the
desired therapeutic effect and to gradually increase the dosage until the
desired
- 9 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW110477P00090PC
effect is achieved.
[030] As used herein, the term "co-administered" includes
administration of diacerein and at least one urate-lowering agent and/or
anti-inflammatory agent either as a single composition or as separate
compositions. Diacerein and at least one urate-lowering agent and/or
anti-inflammatory agent may be administered by the same or different routes of
administration and/or at the same or different time or dosing regimens.
[031] In one embodiment, the invention provides a method of treating
and/or preventing hyperuricemia or a metabolic disorder associated with
hyperuricemia comprising administering to a patient in need thereof a
therapeutically effective amount of a compound selected from the group
consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically acceptable
salt,
an analog, a prodrug, or an active metabolite thereof.
[032] In a preferred embodiment, the therapeutically effective amount of
diacerein is from 10 to 200 mg per day. In another embodiment, the
therapeutically effective amount of a pharmaceutically acceptable salt, an
analog, a prodrug, or an active metabolite of diacerein is equivalent to from
10
to 200 mg of diacerein base per day.
[033] In a preferred embodiment, the active metabolite of diacerein is
nnonoacetylrhein or rhein.
[034] In one embodiment, the metabolic disorder associated with
hyperuricemia is selected from the group consisting of acute gout, chronic
gout,
- 10 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
gout arthritis, gout flares, uric acid nephrolithiasis and gouty nephropathy.
[035] In one embodiment, the method of treating and/or preventing
hyperuricemia or a metabolic disorder associated with hyperuricemia may
further comprise administering to said patient at least one additional
therapeutic
agent selected from the group consisting of anti-inflammatory agents and
urate-lowering agents.
[036] In another embodiment, the invention provides a method of
improving blood uric acid level control in a patient with gout, hyperuricemia
or a
metabolic disorder associated with hyperuricemia comprising administering to
said patient a therapeutically effective amount of a compound selected from
the
group consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically
acceptable
salt, an analog, a prodrug, or an active metabolite thereof.
[037] In another embodiment, the invention provides a method of
treating or preventing hyperuricemia or a metabolic disorder associated with
hyperuricemia in a patient receiving a urate-lowering agent or an
anti-inflammatory agent, comprising administering to said patient a
therapeutically effective amount of a compound selected from the group
consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically acceptable
salt,
an analog, a prodrug, or an active metabolite thereof.
[038] In a preferred embodiment, the method of treating or preventing
hyperuricemia or a metabolic disorder associated with hyperuricemia in a
patient receiving a urate-lowering agent or an anti-inflammatory agent reduces
blood levels of uric acid below the upper end of the normal range in said
- 11 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW110477P00090PC
patient.
[039] However, in some embodiments, the provided methods of treating
and/or preventing hyperuricemia or a metabolic disorder associated with
hyperuricemia, as well as the provided methods of improving blood uric acid
level control in a patient with gout, hyperuricemia or a metabolic disorder
associated with hyperuricemia, do not require and do not comprise a
co-administration of any additional therapeutic agents, including but not
limited
to, urate-lowering agents, anti-inflammatory agents, inhibitors of pH-
activated
proteases and others.
[040] In another embodiment, the invention provides a method of
treatment for hyperuricemia or a metabolic disorder associated with
hyperuricemia in a patient with poor tolerance to therapeutic agents selected
from the group consisting of anti-inflammatory agents and urate-lowering
agents, comprising administering to said patient a therapeutically effective
amount of a compound selected from: 1) diacerein, 2) rhein, and 3) a
pharmaceutically acceptable salt, an analog, a prodrug, or an active
metabolite
thereof.
[041] In a preferred embodiment, the anti-inflammatory agent is
selected from the group consisting of non-steroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, colchicines and a combination thereof.
[042] Examples of NSAIDs include, but are not limited to, arylalkanoic
acids such as acetaminophen; 2-arylpropionic acids such as ibuprofen,
ketorolac and naproxen; n-arylanthranilic acids such as mefenamic acid,
- 12 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW I 10477P00090PC
meclofenamic acid; oxicams such as piroxicam, meloxicam; arylalkanoic acids
such as diclofenac, etodolac, indomethacin, sulindac; and COX-2 inhibitors
such as celecoxib.
[043] In a preferred embodiment, the urate-lowering agent is selected
from the group consisting of xanthine oxidase inhibitors, uricosuric agents,
urate oxidases, urinary alkalinizers and fenofibrate.
[044] Examples of xanthine oxidase inhibitors include, but are not
limited to, allopurinol, oxypurinol and febuxostat. Examples of uricosuric
agents
include, but are not limited to, bucolome, sulphinpyrazone, benzbromarone and
probenecid. Examples of urate oxidases include, but are not limited to,
pegloticase, puricase, rasburicase, uricase and pegylated uricase. Examples of
urinary alkalinizers include, but are not limited to, sodium hydrogen
carbonate,
potassium citrate and sodium citrate.
[045] In a preferred embodiment, the method of treatment lowers blood
levels of uric acid; and/or decreases inflammatory effects of gout arthritis
and
gout flares induced by hyperuricemia; and/or dissolves kidney stones; and/or
reduces the recurrence rate of acute inflammatory arthritis induced by
hyperuricemia; and/or prevents the recurrent hyperuricemia; and/or slows down
the progression of urate nephropathy in said patient.
[046] In another preferred embodiment, the method of treatment
reduces blood levels of uric acid below the upper end of the normal range in
said patient.
- 1.3 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TW'110477P00090PC
[047] Diacerein and an anti-inflammatory agent and/or a urate-lowering
agent may be contained in a single formulation or may be co-administered as
separate formulations.
[048] The invention also provides pharmaceutical compositions for
treating and/or preventing hyperuricemia or a metabolic disorder associated
with hyperuricemia in a patient comprising a therapeutically effective amount
of
a compound selected from the group consisting of: 1) diacerein, 2) rhein, and
3)
a pharmaceutically acceptable salt, an analog, a prodrug, or an active
metabolite thereof.
[049] In a preferred embodiment, the therapeutically effective amount of
diacerein is from 10 to 200 mg per day. In another embodiment, the
therapeutically effective amount of a pharmaceutically acceptable salt, an
analog, a prodrug, or an active metabolite of diacerein is equivalent to from
10
to 200 mg of diacerein base per day.
[050] The invention also provides pharmaceutical compositions
comprising: 1) diacerein, rhein, or a pharmaceutically acceptable salt, a
prodrug,
or an active metabolite thereof, and 2) at least one additional therapeutic
agent.
[051] In one embodiment, the additional therapeutic agent is selected
from the group consisting of anti-inflammatory agents and urate-lowering
agents.
[052] In a preferred embodiment, the additional therapeutic agent is
selected from the group consisting of: 1) xanthine oxidase inhibitors; 2)
uricosuric agents; 3) urate oxidase inhibitors; 4) fenofibrate; 5) NSAIDs; 6)
- 14 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
corticosteroids, and 7) colchicine.
[053] The additional active ingredient can be present in a
controlled-release dosage form or in an immediate release dosage form.
[054] When administered to a patient in need thereof, diacerein, its
pharmaceutically acceptable salts, prodrugs, or active metabolites can be
prepared as pharmaceutical compositions.
[055] The pharmaceutical composition can further include a
pharmaceutically acceptable carrier, and can be in solid or liquid form,
including
but not limited to, tablets, powders, capsules, pellets, solutions,
suspensions,
elixirs, emulsions, gels, creams; patch, or suppositories, including rectal
and
urethral suppositories.
[056] As used herein, the term "pharmaceutically acceptable carrier"
refers to a pharmaceutically acceptable material, composition or vehicle, such
as a liquid or solid filler, diluent, excipient, solvent or encapsulating
material. A
pharmaceutically acceptable carrier is compatible with the other ingredients
of
the composition, with the mode of administration, and not injurious to the
patient. A pharmaceutically acceptable carrier may be either aqueous or
non-aqueous. Pharmaceutically acceptable carriers include gums, starches,
sugars, cellulosic materials, and mixtures thereof. Some examples of materials
which can serve as pharmaceutically-acceptable carriers include, but are not
limited to: (a) sugars, such as lactose, glucose and sucrose; (b) starches,
such
as corn starch and potato starch; (c) cellulose, and its derivatives, such as
sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (d)
powdered tragacanth; (e) malt; (f) gelatin; (g) talc; (h) excipients, such as
cocoa
- 15 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
butter and suppository waxes; (i) oils, such as peanut oil, cottonseed oil,
safflower oil, sesame oil, olive oil, corn oil and soybean oil; (j) glycols,
such as
propylene glycol; (k) polyols, such as glycerin, sorbitol, mannitol and
polyethylene glycol; (I) esters, such as ethyl oleate and ethyl laurate; (m)
agar;
(n) buffering agents, such as magnesium hydroxide, aluminum hydroxide, boric
acid and sodium borate, and phosphate buffers; (o) alginic acid; (p)
pyrogen-free water; (q) isotonic saline; (r) Ringer's solution; (s) ethyl
alcohol; (t)
phosphate buffer solutions; and (u) other non-toxic compatible substances
suitable for use in pharmaceutical compositions.
[057] The compositions of the invention may be administered using
any means known in the art, including but not limited to oral, nasal,
parenteral,
topical, transdermal, or rectal routes of administration. Preferably, the
compositions are adapted for oral or topical administration. For example, the
active ingredient of the composition can be formulated with suitable
excipients
for the preparation of tablets, capsules, pellets, troches, lozenges,
solutions,
powders or granules, suspensions, hard or soft capsules, patches and any
other suitable forms. The methods for preparing the pharmaceutical
compositions and the selection of suitable excipients are known by a skilled
person in the art.
[058] The following Examples demonstrate some aspects of the
invention. The Examples are not meant to limit the invention in any way.
- 16 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
Example 1
A Randomized, Double-Blind, Placebo-Controlled Study for
Diacerein Treatment on Albuminuria in Patients with Type 2
Diabetes Mellitus (DIA-DM01 trial)
[059] Objectives: To evaluate the efficacy and safety of diacerein for
the treatment of albuminuria in patients with type 2 diabetes mellitus.
[060] Primary Endpoints: To compare the change from baseline in the
urinary albumin to creatinine ratio (UACR) after 24 weeks of diacerein or
placebo administrated.
[061] Subjects: Male or female type 2 diabetes patients (BMI 35
kg/m2) with micro-albuminuria.
[062] Procedure: This was a Phase H, prospective, randomized,
double-blind, and parallel comparison study comparing diacerein 50 mg bid
(twice a day) versus placebo to albuminuria in patients with type 2 diabetes
mellitus.
[063] At the screening visit, patients who fulfilled the enrollment criteria
and gave written informed consent entered a three to ten days screening
period.
During the screening period, the baseline UACR was evaluated. If the baseline
UACR was greater than 50 mg/g, the patients were randomized into the
48-week treatment period in the 1:1 ratio (diacerein versus placebo). All
participants were required to be taking stable dose of
angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers
-17-
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWII 0477P00090PC
(ARBs), or both, for three months prior to the study. These agents were
continued throughout the trial. The hypoglycemic medications were maintained
during the study period. The class and/or dosage were changed if clinically
indicated. An introduction of a new treatment or any regimen change to the
pre-existing co-medication that had hypoglycemic or hyperglycemic potential
was allowed during the study with the consent of the clinical investigator.
[064] The hyperuricemia sub-group was assembled from among the
subjects with baseline blood uric acid level higher than 7.0 mg/dL. The
results
of blood uric acid level in the two treatment groups were analyzed by paired
Nest of within-group changes.
[065] The results are shown in Tables 1 and 2 below.
Table 1
flyperurieemia Sub-group Evaluations in the Diaeerein Group
Diacerein Group
Laboratory parameter: Uric Acid (ing/dL)
Baseline week 12 week 24
9 9 7
Mean 8.0667 6.6667 6.5571
Change from baseline -1.40 -1.34
p value (week 12 or 24 vs. baseline) 0.0037 0.0060
- 18 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TVv'110477P00090PC
Table 2
Hyperuricemia Sub-group Evaluations in the Placebo Group
Placebo Group
Laboratory parameter: Uric Acid (mg/dL)
Baseline week 12 week 24
12 11 11
Mean 8.38 7.81 7.70
Change from baseline -0.59 -0.80
p value (week 12 or 24 vs. baseline) 0.3887 0.2567
[066] Subjects (n=76) with diabetic microalbinuria were randomized in a
1:1 ratio to receive twice-daily diacerein 50 mg (n=38), or placebo (n=38) for
24
weeks. The baseline blood levels of uric acid in nine subjects of the
diacerein
group (2 females and 7 males) and twelve subjects of the placebo group (2
females and 10 males) in the hyperuricemia subgroup were above 7.0 mg/dL,
and the mean levels were 8.06 mg/dL and 8.38 mg/dL respectively.
[067] After 12 weeks and 24 weeks of treatment, diacerein can
significantly decrease the blood uric acid levels (Table 1, p value = 0.0037
and
0.0060 in 12 and 24 week, respectively) compared with the baseline. Further,
diacerein can maintain blood uric acid levels below the upper end of the
normal
range (i.e., below 7.0 mg/dL) during the treatment period. In contrast with
the
diacerein-treated group, the blood uric acid level was not improved in the
- 19 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
placebo-treated group (Table 2, p value = 0.3887 and 0.2567 in 12 and 24
VV I\).
[068] As Tables 1 and 2 demonstrate, in the beginning of the treatment,
there were nine people in the diacerein group and twelve people in the placebo
group. After 12 weeks of diacerein treatment, the blood uric acid levels in
six of
the nine patients achieved normal range (the level of uric acid in the blood
in
one female was below 6.0 mgkiL and the levels of uric acid in the blood in
five
males were below 7.0 mg/dL). In contrast, only one of the remaining eleven
patients in the placebo group achieved the normal range (the level of uric
acid
in the blood in one male was below 7.0 mg/dL). The same trend was Also
observed in the 24-week treatment with diacerein and placebo. The levels of
uric acid in the blood in four of the remaining seven patients of the
diacerein
group achieved the normal range (the level of uric acid in the blood in one
female was below 6.0 mg/dL and the levels of uric acid in the blood in three
males were below 7.0 mg/dL), while only three of the remaining eleven patients
in the placebo group achieved the normal range (blood uric acid level in three
males were below 7.0 mg/dL). Figures 1 and 2 further illustrate the results of
the studies: Figure 1 is a graph demonstrating blood uric acid levels in male
patients treated with either diacerein or placebo; and Figure 2 is a graph
demonstrating blood uric acid levels in female patients treated with either
diacerein or placebo.
[069] These results strongly suggest that diacerein can significantly
reduce the blood uric acid levels in patients with hyperuricemia and maintain
the uric acid levels in the normal range over the course of the treatment
period.
- 20 -
CA 02829101 2013-09-04
WO 2012/125359
PCT/US2012/027993
TWI10477P00090PC
Example 2
Case study of diacerein and allopurinol combination therapy in
subjects with chronic clout and hyperuricemia
[070] In DIA-DM01 trial described in Example 1, two subjects enrolled
in the diacerein group had chronic gout history and were currently treating
with
allopurinol.
[071] Case 1: A 70-year-old woman with history of chronic gout and
hyperuricemia was treated with allopurinol since January 2, 2009. Before she
was enrolled in the diacerein trial, her medical treatment was unsatisfactory,
and her blood level of uric acid was 8.3 mg/dL in visit 1 (July 8, 2009).
[072] After 24 weeks of the diacerein "add-on" treatment, the patient's
blood uric acid level was lowered to 7.5 mg/dL. No acute flares were observed
during the treatment period.
[073] Case 2: A 66-year-old man with history of chronic gout and
hyperuricemia was treated with allopurinol since August 27, 2009. Before he
was enrolled in the diacerein trial, his medical treatment was also
unsatisfactory,
and his blood level of uric acid was 9.5 mg/dL in visit 1 (December 18, 2009).
[074] After 12 weeks of the diacerein "add-on" treatment, the patient's
blood uric acid level was reduced to 6.4 mg/dL and was maintained below the
upper end of the normal range.
-21 -
